Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Thrombocythaemia Myelofibrosis-Pipeline Review, H1 2015

Thrombocythaemia Myelofibrosis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Thrombocythaemia Myelofibrosis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Thrombocythaemia Myelofibrosis-Pipeline Review, H1 2015', provides an overview of the Thrombocythaemia Myelofibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thrombocythaemia Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocythaemia Myelofibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Thrombocythaemia Myelofibrosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Thrombocythaemia Myelofibrosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Thrombocythaemia Myelofibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Thrombocythaemia Myelofibrosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Thrombocythaemia Myelofibrosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Thrombocythaemia Myelofibrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Thrombocythaemia Myelofibrosis Overview 6

Therapeutics Development 7

Pipeline Products for Thrombocythaemia Myelofibrosis-Overview 7

Pipeline Products for Thrombocythaemia Myelofibrosis-Comparative Analysis 8

Thrombocythaemia Myelofibrosis-Therapeutics under Development by Companies 9

Thrombocythaemia Myelofibrosis-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Thrombocythaemia Myelofibrosis-Products under Development by Companies 12

Thrombocythaemia Myelofibrosis-Companies Involved in Therapeutics Development 13

Gilead Sciences, Inc. 13

Incyte Corporation 14

MEI Pharma, Inc. 15

Nippon Shinyaku Co., Ltd. 16

Novartis AG 17

Thrombocythaemia Myelofibrosis-Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

buparlisib hydrochloride-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

INCB-39110-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

momelotinib-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

NS-018-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

panobinostat-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

pracinostat-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

simtuzumab-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Thrombocythaemia Myelofibrosis-Recent Pipeline Updates 47

Thrombocythaemia Myelofibrosis-Discontinued Products 58

Appendix 59

Methodology 59

Coverage 59

Secondary Research 59

Primary Research 59

Expert Panel Validation 59

Contact Us 60

Disclaimer 60

List of Tables

Number of Products under Development for Thrombocythaemia Myelofibrosis, H1 2015 7

Number of Products under Development for Thrombocythaemia Myelofibrosis-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Late Stage Development, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Products under Development by Companies, H1 2015 12

Thrombocythaemia Myelofibrosis-Pipeline by Gilead Sciences, Inc., H1 2015 13

Thrombocythaemia Myelofibrosis-Pipeline by Incyte Corporation, H1 2015 14

Thrombocythaemia Myelofibrosis-Pipeline by MEI Pharma, Inc., H1 2015 15

Thrombocythaemia Myelofibrosis-Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 16

Thrombocythaemia Myelofibrosis-Pipeline by Novartis AG, H1 2015 17

Assessment by Monotherapy Products, H1 2015 18

Number of Products by Stage and Target, H1 2015 20

Number of Products by Stage and Mechanism of Action, H1 2015 22

Number of Products by Stage and Route of Administration, H1 2015 24

Number of Products by Stage and Molecule Type, H1 2015 26

Thrombocythaemia Myelofibrosis Therapeutics-Recent Pipeline Updates, H1 2015 47

Thrombocythaemia Myelofibrosis-Discontinued Products, H1 2015 58

List of Figures

Number of Products under Development for Thrombocythaemia Myelofibrosis, H1 2015 7

Number of Products under Development for Thrombocythaemia Myelofibrosis-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Clinical Stage Development, H1 2015 11

Assessment by Monotherapy Products, H1 2015 18

Number of Products by Top 10 Targets, H1 2015 19

Number of Products by Stage and Top 10 Targets, H1 2015 19

Number of Products by Top 10 Mechanism of Actions, H1 2015 21

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 21

Number of Products by Top 10 Routes of Administration, H1 2015 23

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 23

Number of Products by Top 10 Molecule Types, H1 2015 25

Number of Products by Stage and Top 10 Molecule Types, H1 2015 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Gilead Sciences, Inc.

Incyte Corporation

MEI Pharma, Inc.

Nippon Shinyaku Co., Ltd.

Novartis AG

Thrombocythaemia Myelofibrosis Therapeutic Products under Development, Key Players in Thrombocythaemia Myelofibrosis Therapeutics, Thrombocythaemia Myelofibrosis Pipeline Overview, Thrombocythaemia Myelofibrosis Pipeline, Thrombocythaemia Myelofibrosis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com